<DOC>
	<DOC>NCT00087737</DOC>
	<brief_summary>To compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with MDD.</brief_summary>
	<brief_title>Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Outpatients. Sexually active individuals participating in the study must use a medically acceptable form of contraception during the study and for at least 15 days after the last dose of test article Subjects must have a primary diagnosis of major depressive disorder Treatment with DVS233 SR at any time in the past Treatment with venlafaxine (immediate release [IR] or ER) within 90 days of study day 1 Known hypersensitivity to venlafaxine (IR or ER)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>